Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 28428225.
- Also identified by DOI 10.2337/db17-0100 and PMC identifier 7301160.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Renal glucose reabsorption was measured with the stepped hyperglycemic clamp in 15 subjects with type 2 diabetes mellitus (T2DM) and 15 without diabetes after 2 days and after more chronic (14 days) treatment with empagliflozin. Patients with T2DM had significantly greater maximal renal glucose transport (Tm<sub>G</sub>) compared with subjects without diabetes at baseline (459 ± 53 vs. 337 ± 25 mg/min; <i>P</i> < 0.05). Empagliflozin treatment for 48 h reduced the Tm<sub>G</sub> in both individuals with and without diabetes by 44 ± 7 and 53 ± 6%, respectively (both <i>P</i> < 0.001). Tm<sub>G</sub> was further reduced by empagliflozin in both groups on day 14 (by 65 ± 5 and 75 ± 3%, respectively). Empagliflozin reduced the plasma glucose concentration threshold for glucose spillage in the urine similarly in individuals with T2DM and without diabetes to <40 mg/dL, which is well below the normal fasting plasma glucose concentration. In summary, sodium-glucose transporter-2 inhibition with empagliflozin reduces both Tm<sub>G</sub> and threshold for glucose spillage in the urine in patients with T2DM and those without diabetes.
Medical subject headings
- Benzhydryl Compounds
- Diabetes Mellitus, Type 2
- Glucose
- Glucosides
- Hypoglycemic Agents
- Kidney